ADMA Biologics, Inc. revised financial guidance for the years 2024 and 2025. For the years 2024 and 2025, the company expects total revenue now to be more than $330 million and $380 million, respectively, increased from prior guidance of $320 million and $370 million, respectively.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
8.81 USD | +27.13% | +29.37% | +94.91% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+94.91% | 2.04B | |
-2.61% | 89.08B | |
+3.55% | 40.9B | |
-14.40% | 32.25B | |
+55.89% | 25.14B | |
-15.96% | 15.39B | |
-15.50% | 11.91B | |
-41.29% | 11.89B | |
-11.75% | 11.64B | |
+7.87% | 9.03B |
- Stock Market
- Equities
- ADMA Stock
- News ADMA Biologics, Inc.
- ADMA Biologics, Inc. Revises Financial Guidance for the Years 2024 and 2025